From a corporate finance perspective, we analyse the venture capital divestments carried out in June 2018. In this case, we will analyse the operations corresponding to companies such as: Ticketea, Social Point, Prexton Therapeutics and some others.<\/p>\n
From a corporate finance perspective, we analyse the venture capital divestments carried out in June 2018. In this case, we will analyse the operations corresponding to companies such as: Ticketea, Social Point, Prexton Therapeutics and some others.<\/p>\n
We take a look at venture capital divestments in June 2018:<\/a><\/p>\n Firstly, Ticketea<\/a> is a Spanish company dedicated to the management of a digital platform that promotes company events and sells tickets for them. Its investors\/shareholders opted to sell their stakes, especially Seaya Ventures who owned a large percentage of the shares. 100% of the shares were sold to Eventbrite, an online platform for event management and ticket sales. The deal closed with a value of approximately \u20ac17M.<\/p>\n Tambi\u00e9n, la empresa canadiense dedicada a la provisi\u00f3n de soluciones espec\u00edficas de digital media, AcuityAds, ha acordado la adquisici\u00f3n del 100% de los derechos de la empresa espa\u00f1ola Adman Media, por un valor de 12M\u20ac. Entre los principales vendedores se encuentra la firma de venture capital Inveready Capital. Adman Media, con sede en Barcelona e suna empresa dedicada al desarrollo de una plataforma SSP para formatos de outstream video.<\/p>\n Another operation took place in the pharmaceutical sector, Lundbeck<\/a>Denmark-based multinational pharmaceutical company Lundbeck has agreed to acquire 100% from Prexton Therapeutics (a research-based drug discovery company specialising in Parkinson's) owned by Ysios Capital, M Ventures, Forbion, Seroba and Sunstone Capital. The deal was completed for a final value of \u20ac905 million and will give Lundbeck global rights to the Parkinson's treatment.<\/p>\n On the other hand, Siemens Venture Capital, Caixa Capital Risc, Axis, Gilde Healthcare, Kurma Partners, Idinvest Partners, Boehringer Ingelheim have decided to sell their stakes in the developer of a diagnostic platform for hospitals that reduces the time to detect infections and resistance to certain antibiotics in patients, Stat -Dx<\/a>. The buyer is a German company that provides technological solutions in the area of molecular medicine, called Qjagen. The transaction has been closed for a total of \u20ac154 million.<\/p>\n